SecBot SecBot

VCYT

VERACYTE, INC.
Nasdaq· Services-Medical Laboratories· Inc. DE· CIK 0001384101 Healthcare & Medical Devices
$24.01 −0.32 (−1.32%)
Nov 16 4:00 PM ET · prev $24.33
Market cap
$2.0B
Small cap
Consensus
Buy
89% Buy or better · 18 analysts
Median target
$42.50
+77% · range $30.00–65.00
1 year
−38.9%
from $39.28 · Nov 17
30 days
−45.2%
from $43.80
52-week range
$24.00–60.49
−60% from high · low Nov 5
Avg volume 20D
2.78M
Nov 5 spike 14.99M
Short interest
9.56M
≈11.8% of shares · −2.7%
Days to cover
8.2
at average volume
Insider net
−$12.7M
0 buyers · 10 sellers · since May 6
New fund stakes
4
Q2 2026 13F · 0 exits
Filing reports
21
analyzed by SecBot
SecBot read MIXED 11 reports · 90 days
Balance 0 bearish · 1 bullish · 10 neutral oldest → newest, height = score
Avg score ·High conf. 9/11

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

  • Mar 3 ▲ Gilbert Cisneros bought $1,001 - $15,000, last disclosed Apr 8
  • May 5 ▲ Veracyte reported Q1 2026 earnings with total revenue of $139.1M (+2…
  • May 20 to May 22 ▼ 2 days of insider sells: $1.5M by 2 insiders, avg $44.99
  • Jun 4 ▼ 4 insiders sell $8.0M at $50.10
  • Jun 18 ▼ 1 insider sell $197.2K at $52.89
  • Jun 30 ▲ 4 funds open new positions (13F)
  • Sep 1 to Sep 4 ▼ 2 days of insider sells: $942.1K by 4 insiders, avg $43.06
  • Sep 14 to Sep 24 ▼ 3 days of insider sells: $717.8K by 2 insiders, avg $43.47
  • Oct 19 ▼ 1 insider sell $81.5K at $43.70
  • Oct 27 ▼ 2 insiders sell $1.1M at $50.00
  • Nov 4 ▲ Earnings: VCYT Q3 2026 Earnings: EPS $0.51 (+21.8% vs est)
  • Nov 5 ▼ Leerink Partners downgrades

Signal stack

Where each data set points today.

  • InsidersBEARISH

    10 insiders sold $12.7M.

  • InstitutionsBULLISH

    Q2 2026: 31 added (4 new), 16 trimmed or exited. Largest new: Driehaus Capital Management $61.4M, Artemis Investment Management $37.5M.

  • AnalystsBULLISH

    16 of 18 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −2.7% to 9.56M shares. 8.2 days to cover, ≈11.8% of shares.

  • TrendDOWNTREND

    43% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 26.

Who's buying

13F· Q2 2026
4
new positions
0
exits
$135.3M
in new stakes

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts
Buy 89% rate it Buy or better
Strong Buy8Buy8Hold2Sell0Strong Sell0
12-month targets · 10 analysts

Price is below the lowest target. Median implies +77%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 11, 2026Stephens & Co.
MAINTAIN
MAINTAINOverweight
Nov 10, 2026Piper Sandler
MAINTAIN
MAINTAINOverweight
Nov 10, 2026Freedom Capital Markets
MAINTAIN
MAINTAINBuy
Nov 9, 2026UBS
MAINTAIN
MAINTAINBuy
Nov 5, 2026Leerink Partners
DOWNGRADE
DOWNGRADEMarket Perform
Nov 5, 2026Needham
MAINTAIN
MAINTAINBuy
Congressional trades
VCYT trades disclosed by members of Congress, with disclosure delay.
1 members · 1 buys / 0 sells
DateMemberType AmountDisclosed
Mar 3, 2026 Gilbert CisnerosDHouse Veracyte Inc BUY $1K–$15K Apr 7, 2026 +35d

Insider ledger

Form 4
$0
bought · 0 insiders
$12.7M
sold · 10 insiders
DateInsiderTypeValue
Oct 28, 2026
Wygant Jonathan
VP, Chief Accounting Officer
Oct 28, 2026
TAX W/H$65.7K
Oct 27, 2026
Holstein Jens
Director
Oct 27, 2026
SELL$375.0K
Oct 27, 2026
EASTHAM KARIN
Director
Oct 27, 2026
EXERCISE$270.1K
Oct 27, 2026
Holstein Jens
Director
Oct 27, 2026
EXERCISE$264.8K
Oct 27, 2026
EASTHAM KARIN
Director
Oct 27, 2026
SELL$742.6K
Oct 19, 2026
Bhanji Muna
Director
Oct 19, 2026
SELL$81.5K
Sep 24, 2026
Holstein Jens
Director
Sep 24, 2026
SELL$352.5K
Sep 24, 2026
Holstein Jens
Director
Sep 24, 2026
EXERCISE$264.8K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY$1.57$1.44–$1.86-19.5%$634.3M
Reddit
Recent posts
All social signals and their track records

Short side

FINRA· Oct 30, 2026
9,559,148
shares short
-2.7%
vs prior settlement
8.2
days to cover
≈11.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 12, 2026 SEC
Artisan Partners Limited Partnership filed an amended Schedule 13G reporting a 2.9% passive stake in Veracyte as of…
SC 13G/A · Impact 3/10
Nov 5, 2026 Other
Veracyte Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Veracyte (VCYT)
Veracyte stock fell more than 50% after the Company reported on November 4, 2026 that Decipher Prost
Nov 5, 2026 SEC
FMR LLC (Fidelity) filed an amended Schedule 13G reporting a 7.7% passive stake in Veracyte as of September 30, 2026…
SC 13G/A · Impact 3/10
Nov 4, 2026 SEC
Veracyte reported Q3 2026 revenue of $151.8M (+15% YoY), slightly above the $147.2M consensus, and GAAP EPS of $0.38…
8-K · Impact 5/10
Oct 28, 2026 Insider
Wygant Jonathan surrendered for taxes 1,306 shares
VP, Chief Accounting Officer @ $50.31 ($65.7K)
Oct 27, 2026 Insider
Holstein Jens sold 7,500 shares
Director @ $50.00 ($375.0K)
Oct 27, 2026 Insider
EASTHAM KARIN acquired via exercise 10,000 shares
Director @ $27.01 ($270.1K)
Sep 14, 2026 Press
Veracyte acquires Convergent Genomics for $150M upfront plus up to $30M in milestone payments, adding the UroAmp…
Impact 6/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 5, 2026
Press release
Veracyte Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Veracyte (VCYT)
Veracyte stock fell more than 50% after the Company reported on November 4, 2026 that Decipher Prostate volume fell short of its expectations. Levi…
Nov 4, 2026
Earnings result
VCYT Q3 2026 Earnings: EPS $0.51 (+21.8% vs est)
Oct 19, 2026
Press release
Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026
Oral presentations include new Decipher treatment-selection evidence and an OPTIMA breast cancer health economic analysis...
Sep 30, 2026
Short interest
Short Interest: VCYT up 21% to 10.2M shares
Settlement 2026-09-30 | Days to cover: 5.88 | ≈12.66% of shares outstanding (est.)
Sep 25, 2026
Press release
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
Six oral presentations and two posters will highlight Decipher’s prognostic and predictive value in identifying patients’ risk of progression and…

SecBot reports

21 filings · 1 press release · 3 bullish · 2 bearish · 16 neutral
All VCYT filing & press-release reports (22)